Full-Time
Arzt
Posted on 9/10/2026
Synlab
5,001-10,000 employees
Medical diagnostic laboratory services provider
No salary listed
Delmenhorst, Germany
In Person
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Synlab
See people who can refer or advise you
- You are a trained physician with completed medical studies and a German medical license (Approbation).
- You can demonstrate 12 months of experience in direct patient care in accordance with the training regulations.
- You have very good German language skills and good English language skills.
- Care for and advise patients across the full spectrum of outpatient gynecology.
- Perform and learn gynecological examinations, pregnancy checkups, and care for pregnant patients.
- Perform ultrasound examinations, cancer screening, and follow-up care.
- Diagnose and treat gynecological diseases and participate in the daily consultation service.
- Contribute to a smooth, patient-oriented practice workflow.
- Initial experience in gynecology and obstetrics.
SYNLAB provides a full range of medical laboratory services for practicing doctors, clinics, and patients. Its diagnostic tests cover human medicine and are processed through a wide network of labs across 36 countries and four continents, making it a leading partner for laboratory diagnostics in Europe. Tests are performed in certified laboratories using standardized procedures to deliver fast, reliable, high-quality results that doctors use to diagnose and monitor conditions. SYNLAB differentiates itself through its large European footprint, integrated laboratory network, and scale, which enable consistent, timely diagnostics across many sites. The company’s goal is to support better patient care by expanding access to accurate and efficient laboratory testing.
Company Size
5,001-10,000
Company Stage
Acquired
Total Funding
$440M
Headquarters
Munich, Germany
Founded
1998
Get referred to Synlab
See people who can refer or advise you
Simplify's Take
What believers are saying
- SYNLAB won Region Stockholm; operations start April 2027, adding recurring public-health volume.
- SYNLAB sold Slovakia to Unilabs in February 2026, sharpening capital allocation toward denser markets.
- Cinven refinanced SYNLAB with €400 million in May 2026, easing near-term liquidity pressure.
What critics are saying
- Slovakia's antitrust authority fined SYNLAB in May 2026 for cartel coordination with rivals.
- Synnovis' June 2024 ransomware attack still haunts SYNLAB's UK reputation and procurement credibility.
- A failed 2027 refinancing or further cyber breach forces fire-sale disposals and destroys equity value.
What makes Synlab unique
- SYNLAB spans 36 countries, giving doctors one cross-border diagnostics network and local collection points.
- Region Stockholm chose SYNLAB in March 2026 for five-year laboratory medicine services.
- Partnerships with Labcorp and Microba extend specialty testing without building every assay in-house.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Wellness Program
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 1%Region Stockholm engages SYNLAB to expand its medical diagnostic services in Sweden. * The Health and Medical Care Committee awarded SYNLAB Sverige AB the contract for the provision of services within clinical laboratory medicine in the Stockholm region. * This agreement enables SYNLAB to strengthen the region's diagnostic infrastructure and significantly expand its role and presence within the healthcare landscape in Sweden. * SYNLAB will work closely with the regional authority to expand its network while continuing to provide reliable, accessible and high-quality service that benefits patients and professionals. SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, announced today that SYNLAB Sverige AB has been selected by Region Stockholm to provide medical diagnostic services throughout the county. The decision reflects the region's confidence in SYNLAB as a capable and trusted partner for the future of healthcare. The new agreement brings a modern and high-quality medical diagnostic solution to Region Stockholm. It allows SYNLAB to expand its presence in the region and strengthen an essential part of the healthcare system's diagnostic infrastructure. The assignment covers clinical chemistry including pharmacology, clinical microbiology, clinical immunology, and clinical pathology and cytology, as well as the processes needed to ensure safe and efficient sample handling. Within the framework of the agreement, SYNLAB will also operate a network of blood collection points (BCPs) in the western parts of the Stockholm County, the inner city and the southwestern areas. The agreement spans a period of five years, with the option to extend, and operations are planned to begin in April 2027. "We are proud of the trust placed in us to deliver laboratory and sample-collection services to Region Stockholm. Medical diagnostics are vital to the healthcare system. We look forward to working with the region to expand SYNLAB's modern and reliable diagnostic service and to provide strong value for patients and healthcare professionals," says Johanna Kristoffersson, Chief Executive Officer of SYNLAB Sverige AB. With its strong track record of building and managing large-scale operations tailored to local needs and environment, SYNLAB looks forward to expanding its services on behalf of Region Stockholm and contributing to care excellence across the wider region.
Cinven has completed the sale of an indirect minority stake in SYNLAB to Labcorp, a global leader in laboratory services. SYNLAB, a major player in medical diagnostics in Europe, achieved revenues of €2.62 billion in 2024. The companies plan to explore opportunities for Labcorp's specialty tests in Europe and potential collaborations. Labcorp, with nearly 70,000 employees, supported over 75% of new FDA-approved drugs in 2024.
Gómez-Acebo & Pombo has advised the Synlab Group, a leader in medical diagnostic services and specialized tests in Europe, in the sale of Synlab Spain to Eurofins Scientific (EUFI.PA).
Synlab is a medical diagnostic services and specialty testing provider.
EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze OutCinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow30.10.2024 / 07:32 CET/CESTThe issuer is solely responsible for the content of this announcement.Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in SYNLAB, alongside existing shareholders Cinven, Labcorp (subject to regulatory approval), and Qatar Holding LLC. The transaction is subject to regulatory approvals and is expected to close in early 2025. The acquiring entity of Elliott’s shareholding will be Ephios Bidco GmbH (“Ephios Bidco”), an entity controlled by funds managed and/or advised by Cinven and the majority shareholder of SYNLAB AG. Ephios Bidco currently holds approximately 86% of the SYNLAB share capital